摘要
目的探讨国产与进口苯磺酸氨氯地平治疗原发性高血压的临床疗效及经济学价值。方法 80例原发性高血压患者,采取随机数字表法分为观察组和对照组,各40例。观察组给予国产苯磺酸氨氯地平治疗,对照组给予进口苯磺酸氨氯地平治疗,对两组患者临床疗效、不良反应、经济学情况及敏感性进行比较。结果观察组总有效率95.00%与对照组的97.50%比较差异无统计学意义(P>0.05)。观察组不良反应发生率15.00%与对照组的12.50%比较差异无统计学意义(P>0.05)。经济学方面观察组成本/效果显著低于对照组。敏感性方面观察组成本/效果依旧低于对照组。结论应用国产和进口苯磺酸氨氯地平治疗原发性高血压在临床疗效及安全性方面没有显著性差异,但国产苯磺酸氨氯地平所需花费更低,经济学效果更加理想。
Objective To investigate the clinical efficacy and economic evaluation of domestic and imported amlodipine besylate in the treatment of essential hypertension. Methods A total of 80 patients with essential hypertension were divided by random number table method into observation group and control group, with 40 cases in each group. The observation group was treated with domestic amlodipine besylate, and the control group was treated with imported amlodipine besylate. Comparison were made on clinical efficacy, adverse reactions, economic situation and sensitivity between the two groups. Results The observation group had no statistically significant difference in total effective rate as 95.00%, comparing with 97.50% in the control group（P〈0.05）. The observation group had no statistically significant difference in incidence of adverse reactions as 15.00%, comparing with 12.50% in the control group（P〈0.05）. The cost/effectiveness of the observation group in economics is significantly lower than that in the control group, and the cost/effectiveness of the observation group in sensitivity was still lower than that of the control group. Conclusion There is no significant difference in the clinical efficacy and safety of domestic and imported amlodipine besylate in the treatment of essential hypertension, but domestic amlodipine besylate required less cost and better economic results.
作者
叶伟杰
张凡
何秀萍
YE Wei-jie, ZHANG Fan, HE Xiu-ping. （Qingyuan Yangshan County People’ s Hospital, Qingyuan 513100, China）
出处
《中国现代药物应用》
2018年第10期83-85,共3页
Chinese Journal of Modern Drug Application
